Federal and state health policy updates include Medicaid work reporting requirements, court action on CMS guidance, federal funding news, and key California and Pennsylvania legislation affecting rare disease care, prior authorization, HTC access, and copay accumulator policies.

Mark Skinner recognized for more than four decades of leadership in hemophilia advocacy, patient-centered research, and global bleeding disorders policy.

Meet the NBDF Board of Directors and learn how their diverse experiences help shape the future of the bleeding disorders community.

Catch up on the latest federal and state updates from July 2026, including congressional funding updates, Medicaid work requirements coming and new 340b reform proposals

The product is expected to return to market in October of 2026

Catch up on the latest federal and state updates from June 2026, including key legislative developments and advocacy efforts impacting the inheritable bleeding disorders community.

HYMPAVZI® (marstacimab-hncq) is a laboratory-engineered monoclonal antibody that targets an anticoagulant protein known as tissue factor pathway inhibitor. It is administered subcutaneously once a week using a pen-like device.

MASAC recommends routine iron screening for people with bleeding disorders to detect iron deficiency early and improve care.